Low plasma ghrelin concentration is an indicator of the metabolic syndrome

References

• Ferrannini E. Syndrome X. Horm Res 1993; 39((suppl 3))107–11
   PubMedGoogle Scholar
• Reaven G. M. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607
   PubMed Web of Science ®Google Scholar
• Ukkola O., Bouchard C. Clustering of metabolic abnormalities in obese individuals: the role of genetic factors. Ann Med 2001; 33: 79–90
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y., Funahashi T., Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte‐derived bioactive substances. Ann N Y Acad Sci 1999; 892: 146–54
   PubMed Web of Science ®Google Scholar
• Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth‐hormone‐releasing acylated peptide from stomach. Nature 1999; 402: 656–60
   PubMed Web of Science ®Google Scholar
• Kojima M., Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85: 495–522
   PubMed Web of Science ®Google Scholar
• Tschop M., Weyer C., Tataranni P. A., Devanarayan V., Ravussin E., Heiman M. L. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707–9
   PubMed Web of Science ®Google Scholar
• Schofl C., Horn R., Schill T., Schlosser H. W., Muller M. J., Brabant G. Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 4607–10
   PubMed Web of Science ®Google Scholar
• Bacha F., Arslanian S. A. Ghrelin Suppression in Overweight Children: A Manifestation of Insulin Resistance?. J Clin Endocrinol Metab 2005; 90: 2725–30
   PubMed Web of Science ®Google Scholar
• Pöykkö S. M., Kellokoski E., Horkko S., Kauma H., Kesäniemi Y. A., Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003; 52: 2546–53
   PubMed Web of Science ®Google Scholar
• Fagerberg B., Hulten L. M., Hulthe J. Plasma ghrelin, body fat, insulin resistance, and smoking in clinically healthy men: the atherosclerosis and insulin resistance study. Metabolism 2003; 52: 1460–3
   PubMedGoogle Scholar
• Rantala A. O., Kauma H., Lilja M., Savolainen M. J., Reunanen A., Kesaniemi Y. A. Prevalence of the metabolic syndrome in drug‐treated hypertensive patients and control subjects. J Intern Med 1999; 245: 163–74
   PubMed Web of Science ®Google Scholar
• Cummings D. E., Purnell J. Q., Frayo R. S., Schmidova K., Wisse B. E., Weigle D. S. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714–9
   PubMed Web of Science ®Google Scholar
• Whatmore A. J., Hall C. M., Jones J., Westwood M., Clayton P. E. Ghrelin concentrations in healthy children and adolescents. Clin Endocrinol 2003; 59: 649–54
   PubMed Web of Science ®Google Scholar
• Alberti K. G., Zimmet P., Shaw J., IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet 2005; 366: 1059–62
   PubMed Web of Science ®Google Scholar
• Belfiore F., Iannello S. Insulin resistance in obesity: Metabolic mechanisms and measurement methods. Mol Genet Metab 1998; 65: 121–8
   PubMed Web of Science ®Google Scholar
• Bergman R. N., Mittelman S. D. Central role of the adipocyte in insulin resistance. J Basic Clin Physiol Pharmacol 1998; 9: 205–21
   PubMedGoogle Scholar
• Björntorp P., Rosmond R. Hypothalamic origin of the metabolic syndrome X. Ann N Y Acad Sci 1999; 892: 297–307
   PubMed Web of Science ®Google Scholar
• De Courten M., Zimmet P., Hodge A., Collins V., Nicholson M., Staten M., et al. Hyperleptinaemia: the missing link in the metabolic syndrome?. Diabet Med 1997; 14: 200–8
   PubMed Web of Science ®Google Scholar
• Kruszynska Y. T., Mukherjee R., Jow L., Dana S., Paterniti J. R., Olefsky J. M. Skeletal muscle peroxisome proliferator‐activated receptor‐gamma expression in obesity and non‐insulin‐dependent diabetes mellitus. J Clin Invest 1998; 101: 543–8
   PubMedGoogle Scholar
• Langenberg C., Bergstrom J., Laughlin G. A., Barrett‐Connor E. Ghrelin and the Metabolic Syndrome in Older Adults. J Clin Endocrinol Metab 2005; 90: 6448–53
   PubMedGoogle Scholar
• Nagaya N., Kojima M., Uematsu M., Yamagishi M., Hosoda H., Oya H., et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1483–R1487
   PubMed Web of Science ®Google Scholar
• Sonnenberg G. E., Krakower G. R., Kissebah A. H. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004; 12: 180–6
   PubMedGoogle Scholar
• Otto B., Tschop M., Heldwein W., Pfeiffer A. F., Diederich S. Endogenous and exogenous glucocorticoids decrease plasma ghrelin in humans. Eur J Endocrinol 2004; 151: 113–7
   PubMedGoogle Scholar
• Ukkola O. Ghrelin and insulin metabolism. Eur J Clin Invest 2003; 33: 183–5
   PubMedGoogle Scholar
• Gauna C., Meyler F. M., Janssen J. A., Delhanty P. J., Abribat T., van Koetsveld P., et al. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab 2004; 89: 5035–42
   PubMed Web of Science ®Google Scholar
• Gauna C., Delhanty P. J., Hofland L. J., Janssen J. A., Broglio F., Ross R. J., et al. Ghrelin stimulates, whereas des‐octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab 2005; 90: 1055–60
   PubMed Web of Science ®Google Scholar
• Marzullo P., Verti B., Savia G., Walker G. E., Guzzaloni G., Tagliaferri M., et al. The Relationship between Active Ghrelin Levels and Human Obesity Involves Alterations in Resting Energy Expenditure. J Clin Endocrinol Metab 2004; 89: 936–9
   PubMed Web of Science ®Google Scholar
• Ariyasu H., Takaya K., Hosoda H., Iwakura H., Ebihara K., Mori K., et al. Delayed short‐term secretory regulation of ghrelin in obese animals: evidenced by a specific RIA for the active form of ghrelin. Endocrinology 2002; 143: 3341–50
   PubMed Web of Science ®Google Scholar